| Code | CSB-RA023981MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to MEDI-6469, designed to target TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a crucial role in T cell activation, proliferation, and survival. Upon binding with its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes the differentiation of effector and memory T cells. TNFRSF4 signaling is particularly relevant in cancer immunotherapy and autoimmune disease research, as it modulates the balance between effector T cells and regulatory T cells, influencing anti-tumor immunity and inflammatory responses.
MEDI-6469 is an agonistic antibody that stimulates OX40 signaling to enhance T cell activation and has been investigated in clinical trials for its potential to boost anti-tumor immune responses in various cancers. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF4-mediated immune regulation, studying T cell costimulation mechanisms, and exploring therapeutic strategies in immuno-oncology and immune-related disorders.
There are currently no reviews for this product.